EnCare Biotech is privately owned biopharmaceutical company, which was founded in 2014 as a spin off from the University Medical Center Utrecht in The Netherlands. The company’s lead product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin.
EnCare Biotech aims to develop a new therapeutic antibody for the prevention of heart failure after acute myocardial infarction (AMI; heart attack). Directly following AMI an inevitable inflammatory response and dilatation of the heart is initiated, in an attempt of the body to compensate for the damage. Unwanted fibrotic changes in functional areas of the heart may also occur that will further decrease cardiac function, a process called reactive fibrosis. This process of maladaptive changes of the heart (adverse remodeling) is actually leading to chronic heart failure.
The core competencies and networks needed for successful execution of the EnCare business model fall in three categories. First, a sound scientific base is formed by involving the department at UMCU where the project first came to light. The second category of core competencies is vital for the adding of value to the assets and is biased towards manufacturing, development and interaction with regulatory authorities. This category includes expertise in CMC, preclinical development, regulatory affairs, clinical development, quality control and project management. EnCare management has a strong network of experts in all of these fields, who represent an impressive combined track record in the manufacturing and development of biological and antibodies in particular.